HRGN · Harvard Apparatus Regenerative Technology, Inc. · Insider Trading

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 15, 2026 to September 23, 2026. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

On September 11, 2026, the Reporting Person also purchased 361,905 shares of common stock of the Issuer in the Private Placement for an aggregate cash purchase price of $380,000, or $1.05 per share, pursuant to a Securities Purchase Agreement, dated as of September 11, 2026, between the Issuer and the Reporting Person, on the same terms as the other investors in the Private Placement.

On September 11, 2026, the Issuer entered into Securities Purchase Agreements with certain investors pursuant to which the investors purchased in a private placement an aggregate of 2,703,727 shares of common stock at a purchase price of $1.05 per share (the "Private Placement"), which closed on September 11, 2026. Included in the Private Placement, the Reporting Person acquired 683,725 shares of common stock in exchange for the conversion and cancellation of an aggregate of $717,911 of outstanding principal and accrued interest under bridge promissory notes previously issued by the Issuer to the Reporting Person on April 14, 2026, May 13, 2026 and July 16, 2026, pursuant to a Securities Purchase Agreement, dated as of September 11, 2026, between the Issuer and the Reporting Person. The shares issued to the Reporting Person were issued at the same $1.05 per share purchase price, and the notes were cancelled in full upon the closing.

Each bridge note provided that, upon a qualified equity financing of the Issuer, the Reporting Person could elect to convert the full balance of the note (principal and accrued interest) into the equity securities sold in such financing at the per-unit price paid by the purchasers in the financing. Because the conversion price was not fixed until the closing of the Private Placement, the notes were not derivative securities prior to that date pursuant to Rule 16a-1(c)(6). The conversion price became fixed at $1.05 per share upon the closing of the Private Placement on September 11, 2026, and the Reporting Person converted the full balance of each note on that date.

Represents the outstanding principal and accrued interest on the note as of September 11, 2026.

The notes were convertible upon the closing of a qualified equity financing and were scheduled to mature on the earlier of the closing of the Issuer's next capital raise with gross proceeds of at least $5,000,000 or the first anniversary of the note's issue date.

Each bridge note provided that, upon a qualified equity financing of the Issuer, the Reporting Person could elect to convert the full balance of the note (principal and accrued interest) into the equity securities sold in such financing at the per-unit price paid by the purchasers in the financing. Because the conversion price was not fixed until the closing of the Private Placement, the notes were not derivative securities prior to that date pursuant to Rule 16a-1(c)(6). The conversion price became fixed at $1.05 per share upon the closing of the Private Placement on September 11, 2026, and the Reporting Person converted the full balance of each note on that date.

Represents the outstanding principal and accrued interest on the note as of September 11, 2026.

The notes were convertible upon the closing of a qualified equity financing and were scheduled to mature on the earlier of the closing of the Issuer's next capital raise with gross proceeds of at least $5,000,000 or the first anniversary of the note's issue date.

Each bridge note provided that, upon a qualified equity financing of the Issuer, the Reporting Person could elect to convert the full balance of the note (principal and accrued interest) into the equity securities sold in such financing at the per-unit price paid by the purchasers in the financing. Because the conversion price was not fixed until the closing of the Private Placement, the notes were not derivative securities prior to that date pursuant to Rule 16a-1(c)(6). The conversion price became fixed at $1.05 per share upon the closing of the Private Placement on September 11, 2026, and the Reporting Person converted the full balance of each note on that date.

Represents the outstanding principal and accrued interest on the note as of September 11, 2026.

The notes were convertible upon the closing of a qualified equity financing and were scheduled to mature on the earlier of the closing of the Issuer's next capital raise with gross proceeds of at least $5,000,000 or the first anniversary of the note's issue date.

Subject to the Reporting Person's continued employment through each applicable vesting date, the time-based portion of the nonqualified stock option vests and becomes exercisable as follows: 100,000 shares vest upon signing of the applicable award agreement, representing vesting for the six-month period from March 1, 2026 through August 31, 2026, subject to the Reporting Person's continued employment through the date of signing. Thereafter, 16,667 shares vest on the first day of each calendar month commencing September 1, 2026, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date; provided that the final monthly installment will be adjusted as necessary so that no more than 600,000 shares vest under the time-based tranche.

Subject to the Reporting Person's continued employment through the applicable vesting date, the performance-based portion of the nonqualified stock option vests and becomes exercisable in four milestone tranches as follows: (i) 250,000 shares upon the closing of a sale of a controlling stake in the Issuer or the listing of its common stock on a national securities exchange (Nasdaq or NYSE), whichever occurs first, following the grant date; (ii) 125,000 shares if, at any time following the Issuer's initial public offering or the listing of its common stock on a national securities exchange, the volume-weighted average price of the Issuer's common stock equals or exceeds two times (2.0x) the initial public offering price or initial listing price, or such fixed target as may be established by the Compensation Committee, e.g., $3.00 per share, for twenty (20) consecutive trading days; (iii) 125,000 shares upon the first date on which the Issuer has raised at least an additional $10,000,000

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from November 25, 2025 to November 26, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 2, 2025 to September 22, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 21, 2025 to August 29, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 24, 2024 to December 30, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on December 3, 2024, March 3, 2025, June 3, 2025 and September 3, 2025.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 27, 2024 to September 6, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

These warrants were transferred by the Reporting Person to two unaffiliated persons.

These warrants were transferred by the Reporting Person to one unaffiliated person.

These warrants were transferred by the Reporting Person to two unaffiliated persons.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from June 21, 2024 to June 27, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Subject to continued employment or service through the applicable vesting dates, up to 220,640 shall vest in two increments, each for 110,320 shares, each such vesting subject to certain performance milestones set by the Board of Directors of the Issuer.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 27, 2023 to December 29, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 14, 2023 to December 15, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 6, 2023 to December 8, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 11, 2023 to September 15, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.